Filing Flows › Health Care › Neurocrine Biosciences (NBIX)
Neurocrine Biosciences (NBIX) earnings and revenue breakdown
Latest: Q3 2026 · 10-Q filed Nov 2, 2026 · Neurocrine Biosciences (NBIX) Q3 2026 earnings results →
Q3 2026 Revenue up 41% year over year to $1.1B · 18¢ of every $1 of revenue kept as net profit · operating margin 29.5%
Neurocrine Biosciences made $1.1B in Q3 2026 (+41% Y/Y). Operating margin 29.5%, net earnings $206M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Nov 2, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.1B in Q3 2026, up 41% year over year and up 17% from the previous quarter.
Operating profit was $0.33B, a 29.5% margin (down 0.6 points year over year). Of the extra revenue versus Q3 2025, 28% reached operating profit, below the 30% margin then. Total costs grew 42% against revenue growth of 41%. The fastest-growing cost line was Cost of revenue (+90%). Net earnings were $0.21B, down 1% year over year. The effective tax rate was 27.2%.
Operating cash flow was $0.40B (up 74% year over year), 191% of net earnings. Non-cash charges added back $0.04B of depreciation and amortization and $0.05B of share-based compensation. Working capital and other items added $0.09B. Capital expenditures of $0.01B left free cash flow of $0.38B.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 10-Q | Nov 2, 2026 | $1.1B | +41% | 29.5% | $206M | $395M |
| Q2 2026 | 10-Q | Jul 31, 2026 | $959M | +40% | 15.8% | $144M | $136M |
| Q1 2026 | 10-Q | May 5, 2026 | $814M | +42% | 23.7% | $198M | $146M |
| Q4 2025 | 10-K | Feb 11, 2026 | $806M | +28% | 26.2% | $154M | $388M |
| Q3 2025 | 10-Q | Oct 28, 2025 | $795M | +28% | 30.1% | $210M | $228M |
| Q2 2025 | 10-Q | Jul 30, 2025 | $688M | +16% | 21.2% | $108M | $102M |
| Q1 2025 | 10-Q | May 5, 2025 | $573M | +11% | 4.1% | $7.9M | $64.8M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Buys from
- VYGR · Stated in 10-K (named, share not stated) · source
- XENE · Stated in 10-K (named, share not stated) · source
About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing, and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine, and immunological disorders. Our portfolio of products includes U.S. Food and Drug Administration (FDA) approved treatments for tardive dyskinesia (TD), chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency (CAH), and endometriosis and uterine fibroids in collaboration with AbbVie Inc.
In its own words, from its 10-K, filed Feb 11, 2026.
Neurocrine Biosciences against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +41% against the peers' median +11%. Operating margin: 29.5% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
| TECH Bio-Techne | Q1 FY27 | $300M | +5% | 12.2% |
Source: Neurocrine Biosciences 10-Q on SEC EDGAR · CIK 914475 · Biological Products, (No Diagnostic Substances)
Guidance and outlook
13F: who owns NBIX and who is buying
More on NBIX
- How Neurocrine Biosciences makes money: revenue by segment
- Neurocrine Biosciences next earnings date and what analysts expect
- Neurocrine Biosciences stock forecast, price target and fair value
- Who owns Neurocrine Biosciences stock: holders, funds and Congress trades
- Neurocrine Biosciences guidance and outlook
- Is Neurocrine Biosciences a takeover target? LBO and rumors
- Neurocrine Biosciences recalls, complaints and regulation
History
Every quarter: Q3 2026 results · Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results
- Neurocrine Biosciences guidance history: guided vs reported
- Neurocrine Biosciences operating margin by quarter
- Neurocrine Biosciences net income by quarter
- Neurocrine Biosciences free cash flow by quarter
- Neurocrine Biosciences R&D spending by quarter
- Neurocrine Biosciences capital expenditures by quarter